Insider Transactions

Date	Name	Title	Type	Shares Traded	Price Range
Nov 12, 2009	luscinski susan m	Officer	Option Execute	98,550	1.05
Jan 25, 2011	graziano chane	Officer	Disposition (Non Open Market)	11,353	4.08
Jan 25, 2011	Green, David	Officer	Disposition (Non Open Market)	11,409	4.08
Jan 9, 2012	Green, David	Officer	Disposition (Non Open Market)	20,602	3.87
Jan 25, 2011	luscinski susan m	Officer	Disposition (Non Open Market)	5,991	4.08
Jan 9, 2012	luscinski susan m	Officer	Disposition (Non Open Market)	7,656	3.87
Jan 14, 2013	luscinski susan m	Officer	Disposition (Non Open Market)	11,475	4.38
Jan 25, 2011	mcnaughton thomas	Officer	Disposition (Non Open Market)	5,990	4.08
Apr 1, 2009	skystone advisors llc	Beneficial Owner (10% or more)	Disposition (Non Open Market)	2,746,988	n/a
Sep 13, 2010	graziano chane	Officer	Buy	6,200	3.45
Sep 14, 2010	graziano chane	Officer	Buy	21,434	3.55
Sep 15, 2010	graziano chane	Officer	Buy	62,361	3.60
Sep 16, 2010	graziano chane	Officer	Buy	10,005	3.63
Nov 19, 2007	hso limited partnership	Beneficial Owner (10% or more)	Buy	5,043	3.74
Sep 28, 2007	hso limited partnership	Beneficial Owner (10% or more)	Buy	14,254	4.42
Nov 15, 2007	hso limited partnership	Beneficial Owner (10% or more)	Buy	18,378	3.80 - 3.82
Nov 16, 2007	hso limited partnership	Beneficial Owner (10% or more)	Buy	18,299	3.90 - 3.91
Nov 20, 2007	hso limited partnership	Beneficial Owner (10% or more)	Buy	5,617	3.87
Oct 1, 2007	hso limited partnership	Beneficial Owner (10% or more)	Buy	6,136	4.43
Aug 21, 2007	hso limited partnership	Beneficial Owner (10% or more)	Buy	1,738	4.54
Showing 21-40 of 123 transactions Page: 1 2 3 4 5 6 7  See Previous 20 | See Next 20

Stock transaction information provided by EDGAR Online. Harvard Bioscience, Inc. makes no representation or warranty with respect to any of the information contained herein, takes no responsibility for supplementing, updating or correcting any such information and shall have no liability with respect to any such information. This listing does not include derivatives, such as stock option grants or shares purchased through an employee stock purchase plan. For recent transactions, including derivative transactions, see our Section 16 SEC filings page.

Disclaimer:
The information contained within this and other Harvard Bioscience Web pages should be deemed accurate and current as of the date of the most recent update, or if no update information has been provided, the date of issuance. Harvard Bioscience assumes no responsibility for any misincurrances or misstatements which occur as the result of the reading of dated material. Users are strongly encouraged to check dates of issuance and most recent update of any information contained within, or linked to, Harvard Bioscience’s web site. For Harvard Bioscience’s most current information please reference Harvard Bioscience public filings with the Securities and Exchange Commission located at http://www.sec.gov.